Bello et al. examined the data from the French early-access program of alpelisib in combination with fulvestrant in heavily pre-treated HR+/HER2− advanced BC, including CDK4/6 inhibitors, in a real-life setting (median of four previous lines of systemic treatments for advanced disease). Here, CDK4 is linked to breast cancer.